Down syndrome, a congenital disorder stemming from abnormal cell division and differentiation, is most common in newborns fated to neurodevelopmental delays and other health complications. The genetic defect causes the dysfunction of the protein kinase DYRK1A, which is encoded on chromosome 21 and is deeply associated with both Down syndrome and autism spectrum disorder. DYRK1A has attracted attention as a target molecule for treating various diseases. Researchers have now identified the FAM53C protein and its DYRK1A-inhibiting effect that keeps the protein kinase inactive inside the cytoplasm.
